Membrane transporters in drug development
Open accessThe DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Abstract
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the human genome has been proven to have more than 400 membrane transporters, which are divided into two families: ATP binding cassette (ABC) and solute carrier (SLC) transporters [114].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Cited by
Items 801–900 of 1,008
Disposition and clinical implications of protein-bound uremic toxins
Jansen, J., Jankowski, J., Gajjala, P. R., Wetzels, J. F. M., & Masereeuw, R. (2017) · Clinical Science · doi:10.1042/cs20160191 · Cited by 49
Yu, C., Yuan, M., Yang, H., Zhuang, X., & Li, H. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy093 · Cited by 51
Koepsell, H. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0191 · Cited by 49
P‑glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
Martínez-Chávez, A., van Hoppe, S., Rosing, H., Lebre, M. C., Tibben, M. M., Beijnen, J. H., & Schinkel, A. H. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00475 · Cited by 50
Membrane interactions in drug delivery: Model cell membranes and orthogonal techniques
Bunea, A., Rønholt, S., Taboryski, R., & Nielsen, H. M. (2020) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102177 · Cited by 52
Development of Artificial Cell Models Using Microfluidic Technology and Synthetic Biology
Kamiya, K. (2020) · Micromachines · doi:10.3390/mi11060559 · Cited by 53
Kiss, M., Mbasu, R. J., Nicolaï, J., Barnouin, K., Kotian, A., Mooij, M. G., Kist, N., Wijnen, R. M. H., Ungell, A.-L. B., Cutler, P., et al. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000559 · Cited by 49
In Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs
Kunze, A., Huwyler, J., Poller, B., Gutmann, H., & Camenisch, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23851 · Cited by 48
Martinez, M. N., Mochel, J. P., Neuhoff, S., & Pade, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00590-0 · Cited by 55
Fujiwara, R., Maruo, Y., Chen, S., & Tukey, R. H. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.08.018 · Cited by 54
Hummel-Eisenbeiss, J., Hascher, A., Hals, P., Sandvold, M. L., Müller‐Tidow, C., Lyko, F., & Rius, M. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.086801 · Cited by 48
Chung, S. S. W., Wang, X., & Wolgemuth, D. J. (2016) · Endocrinology · doi:10.1210/en.2015-1675 · Cited by 48
Winter, S., Fisel, P., Büttner, F., Rausch, S., D’Amico, D., Hennenlotter, J., Kruck, S., Nies, A. T., Stenzl, A., Junker, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29930 · Cited by 49
Stopfer, P., Gießmann, T., Hohl, K., Hutzel, S., Schmidt, S. C., Ganßer, D., Ishiguro, N., Taub, M. E., Sharma, A., Ebner, T., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13609 · Cited by 48
Drug‐Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
Bashir, B., Stickle, D. F., Chervoneva, I., & Kraft, W. K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12580 · Cited by 48
Folate and choline absorption and uptake: Their role in fetal development
Radziejewska, A., & Chmurzyńska, A. (2018) · Biochimie · doi:10.1016/j.biochi.2018.12.002 · Cited by 48
Ross, E. J., Gordon, E. R., Sothers, H., Darji, R., Baron, O., Haithcock, D. W., Prabhakarpandian, B., Pant, K., Myers, R., Cooper, S. J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93570-5 · Cited by 49
Ai, N., Fan, X., & Ekins, S. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.006 · Cited by 53
Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
Brunet, M., & Pastor‐Anglada, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091755 · Cited by 47
Kikuchi, R., Chothe, P. P., Chu, X., Huth, F., Ishida, K., Ishiguro, N., Jiang, R., Shen, H., Stahl, S. H., Varma, M. V. S., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3062 · Cited by 47
Self-citationProdrug Approach as a Strategy to Enhance Drug Permeability
de Souza, M. M., Gini, A. L. R., Moura, J. A., Scarim, C. B., Chin, C. M., & dos Santos, J. L. (2025) · Pharmaceuticals · doi:10.3390/ph18030297 · Cited by 55
Enzyme‐ and transporter‐mediated beverage–drug interactions: An update on fruit juices and green tea
An, G., Mukker, J. K., Derendorf, H., & Frye, R. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.563 · Cited by 50
Tournier, N., Valette, H., Peyronneau, M., Saba, W., Goutal, S., Kühnast, B., Dollé, F., Scherrmann, J., Cisternino, S., & Bottlaender, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079608 · Cited by 47
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro
Weiß, J., Theile, D., Rüppell, M. A., Speck, T., Spalwisz, A., & Haefeli, W. E. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.010 · Cited by 47
Chan, G. N. Y., Saldivia, V., Yang, Y., Pang, H., de Lannoy, I., & Bendayan, R. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12344 · Cited by 47
Poirier, A., Cascais, A., Bader, U., Portmann, R., Brun, M.-E., Walter, I., Hillebrecht, A., Ullah, M., & Funk, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057943 · Cited by 48
Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J. L., Hilmer, S. N., & Nicolazzo, J. A. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 51
Yin, J., Duan, H., & Wang, J. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236158 · Cited by 47
Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression
Mayati, A., Moreau, A., Vée, M. L., Stieger, B., Denizot, C., Parmentier, Y., & Fardel, O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040764 · Cited by 54
Three-dimensional in vitro gut model on a villi-shaped collagen scaffold
Yi, B., Shim, K. Y., Ha, S. K., Han, J., Hoang, H.-H., Choi, I., Park, S., & Sung, J. H. (2017) · BioChip Journal · doi:10.1007/s13206-017-1307-8 · Cited by 50
Zou, L., Stecuła, A., Gupta, A., Prasad, B., Chien, H., Yee, S. W., Wang, L., Unadkat, J. D., Stahl, S. H., Fenner, K. S., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111153 · Cited by 48
Self-citationNanotechnology-Assisted Microfluidic Systems: From Bench to Bedside
Rabiee, N., Ahmadi, S., Fatahi, Y., Rabiee, M., Bagherzadeh, M., Dinarvand, R., Bagheri, B., Zarrintaj, P., Saeb, M. R., & Webster, T. J. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0353 · Cited by 49
Classification of drugs for evaluating drug interaction in drug development and clinical management
Maeda, K., Hisaka, A., Ito, K., Ohno, Y., Ishiguro, A., Sato, R., & Nagai, N. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100414 · Cited by 50
Acetylation turns leucine into a drug by membrane transporter switching
Churchill, G. C., Strupp, M. L., Factor, C., Brémovà-Ertl, T., Factor, M., Patterson, M. C., Platt, F. M., & Galione, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95255-5 · Cited by 47
Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes
Bi, Y., Scialis, R. J., Lazzaro, S., Mathialagan, S., Kimoto, E., Keefer, J., Zhang, H., Vildhede, A. M., Costales, C., Rodrigues, A. D., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0051-2 · Cited by 48
Veiga-Matos, J., Morales, A. I., Prieto, M., Remião, F., & Silva, R. V. D. S. (2023) · Molecules · doi:10.3390/molecules28227532 · Cited by 50
Zur, M., Hanson, A. S., & Dahan, A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.11.007 · Cited by 47
Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity
Tu, M., Li, L., Lei, H., Ma, Z., Chen, Z., Sun, S., Xu, S., Zhou, H., Zeng, S., & Jiang, H. (2014) · Toxicology · doi:10.1016/j.tox.2014.04.007 · Cited by 48
Transporter biology in drug approval: Regulatory aspects
Maeda, K., & Sugiyama, Y. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.012 · Cited by 46
Self-citationInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors
Khurana, V., Minocha, M., Pal, D., & Mitra, A. K. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2014-0014 · Cited by 50
Poirier, A., Portmann, R., Cascais, A., Bader, U., Walter, I., Ullah, M., & Funk, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058248 · Cited by 48
Sager, J. E., Tripathy, S., Price, L., Nath, A., Chang, J. S., Stephenson‐Famy, A., & Isoherranen, N. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.007 · Cited by 47
Narumi, K., Sato, Y., Kobayashi, M., Furugen, A., Kasashi, K., Yamada, T., Teshima, T., & Iseki, K. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2091 · Cited by 48
Auvity, S., Caillé, F., Marie, S., Wimberley, C., Bauer, M., Langer, O., Buvat, I., Goutal, S., & Tournier, N. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210104 · Cited by 47
Chedik, L., Bruyère, A., Bacle, A., Potin, S., Vée, M. L., & Fardel, O. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1487398 · Cited by 49
Qosa, H., Avaritt, B. R., Hartman, N. R., & Volpe, D. A. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3665-x · Cited by 46
Barnett, S., Ogungbenro, K., Ménochet, K., Shen, H., Humphreys, W. G., & Galetin, A. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253062 · Cited by 46
Cormerais, Y., Pagnuzzi‐Boncompagni, M., Schrötter, S., Giuliano, S., Tambutté, É., Endou, H., Wempe, M. F., Pagès, G., Pouysségur, J., & Picco, V. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14176 · Cited by 52
Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery
Kou, L., Yao, Q., Zhang, H., Chu, M., Bhutia, Y. D., Chen, R., & Ganapathy, V. (2020) · Cancers · doi:10.3390/cancers12102837 · Cited by 50
Kimoto, E., Costales, C., West, M. A., Bi, Y., Vourvahis, M., Rodrigues, A. D., & Varma, M. V. S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2434 · Cited by 47
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
Neuvonen, M., Tornio, A., Hirvensalo, P., Backman, J. T., & Niemi, M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2429 · Cited by 47
Self-citationDavenport, J. M., Covington, P. S., Bonifacio, L., McIntyre, G., & Venitz, J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.442 · Cited by 45
Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs
Deng, F. Y., Sjöstedt, N., Santo, M., Neuvonen, M., Niemi, M., & Kidron, H. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106362 · Cited by 50
Self-citationGupta, M., Feng, J., & Bhisetti, G. (2024) · Molecules · doi:10.3390/molecules29061264 · Cited by 48
Rej, R. K., Allu, S. R., Roy, J., Acharyya, R. K., Kiran, I. N. C., Addepalli, Y., & Dhamodharan, V. (2024) · Pharmaceuticals · doi:10.3390/ph17040494 · Cited by 55
Transporters in drug development: advancing on the Critical Path
Huang, S. M., & Woodcock, J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3124 · Cited by 45
Self-citationFisel, P., Renner, O., Nies, A. T., Schwab, M. G., & Schaeffeler, E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.876990 · Cited by 45
Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids
Martinez-Guerrero, L., & Wright, S. H. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204206 · Cited by 45
Self-citationChu, X., Zhang, Z., Yabut, J. A., Horwitz, S., Levorse, J. M., Li, X., Zhu, L., Lederman, H., Ortiga, R., Strauss, J. R., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074179 · Cited by 48
Self-citationPeters, J., Eggers, K., Oswald, S., Block, W., Lütjohann, D., Lämmer, M., Venner, M., & Siegmund, W. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042267 · Cited by 45
In vitro blood–brain barrier permeability predictions for GABAA receptor modulating piperine analogs
Eigenmann, D. E., Dürig, C., Jähne, E. A., Smieško, M., Culot, M., Gosselet, F., Cecchelli, R., Helms, H. C. C., Brodin, B., Wimmer, L., et al. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.03.029 · Cited by 45
Karlgren, M., Simoff, I., Backlund, M., Wegler, C., Keiser, M., Handin, N., Müller, J., Lundquist, P., Jareborg, A.-C., Oswald, S., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.018 · Cited by 45
Li, N., Zhou, T., Wu, F., Wang, R., Zhao, Q. S., Zhang, J., Yang, B., & Ma, B. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563595 · Cited by 55
Ikeda, S., Sugiyama, H., Tokuhara, H., Murakami, M., Nakamura, M., Oguro, Y., Aida, J., Morishita, N., Sogabe, S., Dougan, D. R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00432 · Cited by 47
Crofton, K. M., Bassan, A., Behl, M., Chushak, Y. G., Fritsche, E., Gearhart, J. M., Marty, M. S., Mumtaz, M. M., Pavan, M., Ruíz, P., et al. (2022) · Computational Toxicology · doi:10.1016/j.comtox.2022.100223 · Cited by 47
Patel, C. G., Ogasawara, K., & Akhlaghi, F. (2012) · Xenobiotica · doi:10.3109/00498254.2012.713531 · Cited by 45
Microcystin-LR Induces Apoptosis via NF-κB /iNOS Pathway in INS-1 Cells
Ji, Y. W., Gao, L., Chen, G., Huang, B., Zhang, X., Shen, K., & Wu, S. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074722 · Cited by 46
Pfeifer, N. D., Goss, S., Swift, B., Ghibellini, G., Ivanović, M., Heizer, W. D., Gangarosa, L. M., & Brouwer, K. L. R. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.21 · Cited by 45
Self-citationEllens, H. M., Deng, S., Coleman, J., Bentz, J., Taub, M. E., Ragueneau, I., Chung, S. P., Herédi‐Szabó, K., Neuhoff, S., Palm, J. E., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050542 · Cited by 45
Self-citationNovel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors
Saran, C., Sundqvist, L., Ho, H. S. S., Niskanen, J., Honkakoski, P., & Brouwer, K. L. R. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000828 · Cited by 44
Self-citationIsoherranen, N., Lutz, J. D., Chung, S. P., Hachad, H., Levy, R. H., & Ragueneau, I. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300192g · Cited by 44
Kusuhara, H., Miura, M., Yasui‐Furukori, N., Yoshida, K. J., Akamine, Y., Yokochi, M., Fukizawa, S., Ikejiri, K., Kanamitsu, K., Uno, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048330 · Cited by 44
Self-citationLagadec, M., Doblas, S., Giraudeau, C., Ronot, M., Lambert, S. A., Fasseu, M., Paradis, V., Moreau, R., Pastor, C. M., Vilgrain, V., et al. (2014) · Radiology · doi:10.1148/radiol.14140313 · Cited by 44
Nature and uses of fluorescent dyes for drug transporter studies
Fardel, O., Vée, M. L., Jouan, E., Denizot, C., & Parmentier, Y. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1053462 · Cited by 45
Li, Y., Lu, J., & Paxton, J. W. (2012) · Current Drug Metabolism · doi:10.2174/1389200211209050624 · Cited by 48
Effects of Proton Pump Inhibitors on Metformin Pharmacokinetics and Pharmacodynamics
Kim, A., Chung, I., Yoon, S. H., Yu, K., Lim, K. S., Cho, J., Lee, H., Jang, I., & Chung, J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055616 · Cited by 49
Benson, E. A., Eadon, M. T., Desta, Z., Liu, Y., Lin, H., Burgess, K., Segar, M. W., Gaedigk, A., & Skaar, T. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00111 · Cited by 44
Sauzay, C., White‐Koning, M., Hennebelle, I., Deluche, T., Delmas, C., Imbs, D. C., Chatelut, É., & Thomas, F. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.012 · Cited by 44
Salvia miltiorrhizaRoots against Cardiovascular Disease: Consideration of Herb-Drug Interactions
Chen, F., Li, L., & Tian, D. (2017) · BioMed Research International · doi:10.1155/2017/9868694 · Cited by 44
Geographic Differences in Persistent Organic Pollutant Levels of Yellowfin Tuna
Nicklisch, S. C. T., Bonito, L. T., Sandin, S. A., & Hamdoun, A. M. (2017) · Environmental Health Perspectives · doi:10.1289/ehp518 · Cited by 47
Cholesterol metabolism in drug‑resistant cancer (Review)
Yan, A., Jia, Z., Qiao, C., Wang, M., & Ding, X. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5124 · Cited by 60
Highlights in targeted nanoparticles as a delivery strategy for glioma treatment
Luiz, M. T., Filippo, L. D. D., Tofani, L. B., de Araújo, J. T. C., Dutra, J. A. P., Marchetti, J. M., & Chorilli, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120758 · Cited by 44
Ahmadimoghaddam, D., Hofman, J., Zemánková, L., Nachtigal, P., Doleželová, E., Červený, L., Čečková, M., Mičuda, S., & Štaud, F. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs160 · Cited by 44
Quantifying the impact of transporters on cellular drug permeability
Matsson, P., Fenu, L. A., Lundquist, P., Wiśniewski, J. R., Kansy, M., & Artursson, P. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.009 · Cited by 44
A critical assessment of in vitro tissue models for ADME and drug delivery
Vellonen, K., Malinen, M. M., Mannermaa, E., Subrizi, A., Toropainen, E., Lou, Y., Kidron, H., Yliperttula, M. L., & Urtti, A. O. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.044 · Cited by 54
Sugimoto, H., Matsumoto, S.-I., Tachibana, M., Niwa, S.-I., Hirabayashi, H., Amano, N., & Moriwaki, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22652 · Cited by 43
Greupink, R., Dillen, L., Monshouwer, M., Huisman, M. T., & Rüssel, F. G. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.09.009 · Cited by 43
Reyner, E. L., Sevidal, S., West, M. A., Clouser-Roche, A., Freiwald, S., Fenner, K. S., Ullah, M., Lee, C. A., & Smith, B. J. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.051193 · Cited by 47
Self-citationCytochrome P450 Inhibitory Properties of Common Efflux Transporter Inhibitors
Englund, G., Lundquist, P., Skogastierna, C., Johansson, J., Hoogstraate, J. A., Afzelius, L., Andersson, T. B., & Projean, D. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054932 · Cited by 44
Interactions of bilastine, a new oral H1antihistamine, with human transporter systems
Lucero, M. L., Gonzalo, A., Ganza, Á., Leal, N., Soengas, I., Ioja, E., Gedey, S., Jahic, M., & Bednarczyk, D. (2012) · Drug and Chemical Toxicology · doi:10.3109/01480545.2012.682653 · Cited by 43
Mooij, M. G., van de Steeg, E., van Rosmalen, J., Windster, J. D., de Koning, B. A. E., Vaes, W. H. J., van Groen, B. D., Tibboel, D., Wortelboer, H. M., & de Wildt, S. N. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068577 · Cited by 43
El‐Kattan, A. F., Varma, M. V. S., Steyn, S. J., Scott, D. O., Maurer, T. S., & Bergman, A. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2024-z · Cited by 46
Thakare, R. N., Gao, H., Kosa, R. E., Bi, Y., Varma, M. V. S., Cerny, M. A., Sharma, R., Kühn, M., Huang, B., Liu, Y., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.075275 · Cited by 47
Curreli, F., Belov, D. S., Kwon, Y. D., Ramesh, R. R., Furimsky, A. M., O’Loughlin, K. G., Byrge, P. C., Iyer, L., Mirsalis, J. C., Kurkin, A. V., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.062 · Cited by 44
Detection of Chemical Engagement of Solute Carrier Proteins by a Cellular Thermal Shift Assay
Hashimoto, M., Girardi, E., Eichner, R., & Superti‐Furga, G. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00270 · Cited by 47
GM1 Oligosaccharide Crosses the Human Blood–Brain Barrier In Vitro by a Paracellular Route
Biase, E. D., Lunghi, G., Maggioni, M., Fazzari, M., Pomè, D. Y., Loberto, N., Ciampa, M. G., Fato, P., Mauri, L., Sevin, E., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082858 · Cited by 43
Intestinal membrane transporter-mediated approaches to improve oral drug delivery
Pangeni, R., Kang, S., Jha, S. K., Subedi, L., & Park, J. W. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00515-1 · Cited by 43
Sandeep, M. S., Vemulapalli, S., Puneeth, Y., Pingili, R. B., & Babu, K. N. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.819885 · Cited by 43
Salphati, L., Chu, X., Chen, L., Prasad, B., Dallas, S., Evers, R., Mamaril-Fishman, D., Geier, E. G., Kehler, J. R., Kunta, J. R., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057976 · Cited by 43
Self-citation
Metadata
- Authors
- The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Wah Yee, S., Zamek-Gliszczynski, M. J., & Zhang, L.
- Affiliations
- University of California, San Francisco (US)
- United States Food and Drug Administration (US)
- Boehringer Ingelheim (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Abbott (United States) (US)
- Eli Lilly (United States) (US)
- Novartis (United States) (US)
- RIKEN (JP)
- German Cancer Research Center (DE)
- Western University (CA)
- GlaxoSmithKline (United Kingdom) (GB)
- Genentech (US)
- University of Maryland, Baltimore (US)
- University of Arizona (US)
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-03
- Volume
- 9
- Issue
- 3
- Pages
- 215-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3326076
- OpenAlex
- W2079197876
- Cited by
- 3,340
- References
- 225
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 153 · 2023: 175 · 2022: 180 · 2021: 237 · 2020: 187 · 2019: 219 · 2018: 234 · 2017: 216 · 2016: 242 · 2015: 233 · 2014: 248 · 2013: 316 · 2012: 254
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- National Institutes of Health (GM61390)
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences (GM61390, R01GM041935, U19GM061390, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080801, R01DK061425)
- National Institute of Environmental Health Sciences (P30ES006694)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- membrane transporters, drug transporters, drug-drug interactions, pharmacokinetics, drug absorption, drug disposition, drug development, drug safety and efficacy, drug labeling
- MeSH terms
- Animals, Computer Simulation, Decision Trees, Drug Interactions, Drug Evaluation, Preclinical, Humans, Drug Approval, Mice, Knockout, Membrane Transport Proteins, Mice, Prescription Drugs, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.